Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 196

1.

Molecular genetic tests for JAK2V617F, Exon12_JAK2 and MPLW515K/L are highly informative in the evaluation of patients suspected to have BCR-ABL1-negative myeloproliferative neoplasms.

dos Santos MT, Mitne-Neto M, Miyashiro K, Chauffaille Mde L, Rizzatti EG.

J Clin Pathol. 2014 Feb;67(2):176-8. doi: 10.1136/jclinpath-2013-201822. Epub 2013 Aug 28.

2.

The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms.

Lin Y, Liu E, Sun Q, Ma J, Li Q, Cao Z, Wang J, Jia Y, Zhang H, Song Z, Ai X, Shi L, Feng X, Li C, Wang J, Ru K.

Am J Clin Pathol. 2015 Jul;144(1):165-71. doi: 10.1309/AJCPALP51XDIXDDV.

PMID:
26071474
3.

Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.

Hummel JM, Kletecka MC, Sanks JK, Chiselite MD, Roulston D, Smith LB, Czuchlewski DR, Elenitoba-Johnson KS, Lim MS.

Diagn Mol Pathol. 2012 Sep;21(3):176-83. doi: 10.1097/PDM.0b013e318246975e.

PMID:
22847163
4.

[JAK2 V617F and exon 12 genetic variations in Korean patients with BCR/ABL1-negative myeloproliferative neoplasms].

Kim JT, Cho YG, Choi SI, Lee YJ, Kim HR, Jang SJ, Moon DS, Park YJ, Park G.

Korean J Lab Med. 2010 Dec;30(6):567-74. doi: 10.3343/kjlm.2010.30.6.567. Korean.

5.

Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow.

Schnittger S, Bacher U, Eder C, Dicker F, Alpermann T, Grossmann V, Kohlmann A, Kern W, Haferlach C, Haferlach T.

Haematologica. 2012 Oct;97(10):1582-5. doi: 10.3324/haematol.2012.064683. Epub 2012 Apr 17.

6.

Detection of MPL exon10 mutations in 103 Chinese patients with JAK2V617F-negative myeloproliferative neoplasms.

Chen X, Qi X, Tan Y, Xu Z, Xu A, Zhang L, Wang H.

Blood Cells Mol Dis. 2011 Jun 15;47(1):67-71. doi: 10.1016/j.bcmd.2011.04.004. Epub 2011 May 8.

PMID:
21555228
7.

TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.

Martínez-Avilés L, Besses C, Álvarez-Larrán A, Torres E, Serrano S, Bellosillo B.

Ann Hematol. 2012 Apr;91(4):533-41. doi: 10.1007/s00277-011-1330-0. Epub 2011 Sep 9.

PMID:
21904853
8.

The mutation profile of JAK2, MPL and CALR in Mexican patients with Philadelphia chromosome-negative myeloproliferative neoplasms.

Labastida-Mercado N, Galindo-Becerra S, Garcés-Eisele J, Colunga-Pedraza P, Guzman-Olvera V, Reyes-Nuñez V, Ruiz-Delgado GJ, Ruiz-Argüelles GJ.

Hematol Oncol Stem Cell Ther. 2015 Mar;8(1):16-21. doi: 10.1016/j.hemonc.2014.12.002. Epub 2015 Jan 21.

9.

A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms.

Fantasia F, Di Capua EN, Cenfra N, Pessina G, Mecarocci S, Rago A, Cotroneo E, Busanello A, Equitani F, Lo-Coco F, Nervi C, Cimino G.

Ann Hematol. 2014 Apr;93(4):609-16. doi: 10.1007/s00277-013-1920-0. Epub 2013 Oct 31.

10.

Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology.

Tefferi A, Noel P, Hanson CA.

J Mol Diagn. 2011 Sep;13(5):461-6. doi: 10.1016/j.jmoldx.2011.05.007. Epub 2011 Jun 30.

11.

Molecular characterization of chronic myeloproliferative neoplasias in México.

Ruiz-Argüelles GJ, Garcés-Eisele J, Ortiz-López R, Rivas-Llamas R, Gómez-Almaguer D, Ruiz-Delgado GJ.

Hematology. 2009 Oct;14(5):261-5. doi: 10.1179/102453309X439836.

PMID:
19843380
12.

Differences in the JAK2 and MPL mutation status in the cell lineages of the bcr/abl-negative chronic myeloproliferative neoplasm subtypes.

Toyama K, Karasawa M, Yokohama A, Mitsui T, Uchiumi H, Saitoh T, Handa H, Murakami H, Nojima Y, Tsukamoto N.

Intern Med. 2011;50(21):2557-61. Epub 2011 Nov 1.

13.

[Expression of JAK2V617F and MPLW515L/K mutation in 30 suspected cases of early myeloproliferative disorders].

Fan Z, Zhang R, Shen YM, Fei HR, Zhu ZL, Cen JN.

Zhonghua Xue Ye Xue Za Zhi. 2008 Sep;29(9):611-4. Chinese.

PMID:
19175989
14.

The analysis of JAK2 and MPL mutations and JAK2 single nucleotide polymorphisms in MPN patients by MassARRAY assay.

Zhang SJ, Qiu HX, Li JY, Shi JY, Xu W.

Int J Lab Hematol. 2010 Aug 1;32(4):381-6. doi: 10.1111/j.1751-553X.2009.01208.x. Epub 2010 Mar 23.

PMID:
20331763
15.

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.

Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ, McClure RF, Litzow MR, Gilliland DG, Tefferi A.

Blood. 2006 Nov 15;108(10):3472-6. Epub 2006 Jul 25.

16.

[JAK2V617F mutation and TNF-α expression in myeloproliferative neoplasms and their correlation].

Sun CC, Li Y, Tian WJ, Chen YJ, Zhang LY, Liu X, Shan NN.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Aug;22(4):1022-6. doi: 10.7534/j.issn.1009-2137.2014.04.025. Chinese.

PMID:
25130821
17.

JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.

Kilpivaara O, Levine RL.

Leukemia. 2008 Oct;22(10):1813-7. doi: 10.1038/leu.2008.229. Epub 2008 Aug 28. Review.

PMID:
18754026
18.

[A quantitative assay for JAK2 mutation in 135 patients with chronic myeloproliferative neoplasms].

Chao HY, Shen YM, Zhang R, Feng YF, Cen JN, Yao L, Shen HJ, Zhu ZL, Xue YQ.

Zhonghua Xue Ye Xue Za Zhi. 2009 May;30(5):321-5. Chinese.

PMID:
19799128
19.

[Relationship between Calreticulin Gene Mutation and JAK2/MPL Negative Myeloproliferative Neoplasms].

Dong L, Shen XL, Wei W.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Oct;23(5):1532-4. doi: 10.7534/j.issn.1009-2137.2015.05.060. Review. Chinese.

PMID:
26524072
20.

[JAK2V617F mutation in the patients with myeloproliferative disorder and its relation with clinical characteristics].

Zhu JF, Liu Y, Liu P, Jia MF, Cheng J, Zhao L.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Aug;19(4):916-20. Chinese.

PMID:
21867614
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk